Clinical Trial

Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to explore the efficacy of afatinib in NSCLC harbouring EGFR PACC mutation subtype. The main question it aims to answer is: Afatinib is active in patients with advanced NSCLC harbouring EGFR PACC mutation subtype. Participants will undergo screening, follow by treatment if eligible for study participation and then enter follow up phase after study medication has stopped. Patients will take afatinib 40mg daily continuously, until the development of progressive disease or meeting discontinuation criteria. A treatment cycle is defined as 28 days.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-09-25; most recent amendment 2025-07-22.
Status change: Not Yet Recruiting → Recruiting 2024-05-15
Trial Details
NCT Number NCT06062823
Lead Sponsor National University Hospital, Singapore
Conditions NSCLC
Enrollment 35 participants
Start Date 2024-03-25
Primary Completion 2026-10 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-24